CIMG Acquires 100% Equity of Daren Technology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Source: Newsfilter
- Acquisition Agreement: CIMG's wholly-owned subsidiary DZR signed a share purchase agreement on February 5, 2026, to acquire 100% of Daren's equity for approximately $40 million in stock, with the transaction expected to close within 30 days, marking a strategic expansion into the biopharmaceutical sector.
- Phased Payment Structure: The purchase consideration will be released in four phases—6%, 14%, 28%, and 52%—based on Daren's performance targets over a 3.5-year period, ensuring CIMG maintains ongoing oversight and incentives tied to Daren's performance.
- Performance Targets Set: Daren must achieve increasing audited revenue targets of $29 million, $71 million, $143 million, and $257 million from April 2026 to September 2029, reflecting CIMG's confidence in Daren's growth potential and providing a clear path for revenue growth.
- Strategic Diversification: CIMG's Chairwoman and CEO Alice Wang stated that this acquisition is a key step in the company's diversification strategy, with plans to increase investments in the biopharmaceutical field, leveraging technological integration and model innovation to build a new growth engine and enhance market competitiveness.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
